Neurotology drug developer Otonomy (NSDQ:OTIC) is expanding a Phase 1/2 trial of OTO-413 in patients with difficulty with speech-in-noise tests. In the trial, clinical investigators administer the drug as a single intratympanic injection. The company said that OTO-413 showed promise in improving hearing in a dose escalation efficacy cohort. The randomized, double-blind, placebo-controlled Phase 1/2…